Action ST OncoKit

Testing for main genomic biomarkers with clinical value in the diagnosis, prognosis, sensitivity and/or therapeutic resistance of a wide range of solid tumors, such as lung, breast, and colorectal cancer, among others, by NGS

24 rxn

NGS sequencing

IMG-419

Illumina NextSeq 500 and Illumina NextSeq 550DX

  • It detects point mutations (SNVs), small insertions and deletions (INDELs), structural variants, and copy number variants (CNVs) throughout the genome.
  • UMI molecular barcoding to increase the sensitivity of the bioinformatics analysis.
  • Included analysis software: Data Genomics.
  • Coverage: >99% of bases covered at 200X.
  • Uniformity: 98% of bases covered at >20% of mean coverage.
  • Sensitivity: >99%.
  • Specificity: >99%.
  • Limit of detection (LOD) for SNVs, INDELs, and structural variants is 5%.
  • Limit of detection for CNVs is 2.4 total copies for copy number gains, which means 4 copies at 30% of tumor burden, and 1.8 total copies for copy number losses, which is 1 copy at 20% of tumor burden.
  • Compliant with ISO 9001 and ISO 14001 quality specifications regarding manufacturing materials.
  • Compatible sequencers: Illumina NextSeq 500 and Illumina NextSeq 550DX.
  • Number of reactions: 24.
  • Number of samples per run: Mid Output v2.5 kit (150 cycles): 8 samples.
  • Sequencing: Paired-end (2 x 75 cycles).
  • Amount of DNA per sample: 10-200 ng.
  • Analyzed genomic region: 500 Kb.
  • Sample type: DNA from peripheral blood or paraffin-embedded tissue.

Action ST OncoKit

Fill in the form to request this kit.

Call us at +34 963 212 340

Or write to us at info@healthincode.com